Tese
Construção e avaliação do potencial protetor, em modelo murino, de diferentes construções do Vaccinia Virus Ankara Modificado (MVA) expressando a proteína E de Dengue Virus sorotipos 1, 2 e 4.
Fecha
2019-09-30Autor
Sabrynna Brito Oliveira
Institución
Resumen
Dengue is the main arbovirus that affecting humans and a serious public health
problem. The four dengue virus serotypes (DENV1, 2, 3 and 4) are transmitted
through the bite of female Aedes mosquitoes. A vaccine available worldwide has
immunological gaps, which motivates further research for an effective vaccine.
The Modified Vaccinia Ankara Virus (MVA) is among the most advanced and
intensely studied viral vectors worldwide, and is considered as an excellent tool
for vaccine generation. The aim of this work was to construct recombinant MVAs
expressing the protein E of DENV1, 2 and 4 and to evaluate the protective
potential of these constructs in a murine model. Synthetic genes coding for
protein E from DENV1, 2 and 4 were designed, optimized, commercially obtained
and subcloned into plasmid pLW44, giving rise to transfer plasmids used in the
construction of recombinant viruses. Chicken embryo fibroblast cultures – CEF,
or BHK-21 were infected with MVA and transfected with the transfer plasmids
pLW44-DENV1, pLW44-DENV2 and pLW44-DENV4 for the construction of
recombinant MVAs (rMVA). The generated rMVAs had their correct construction
confirmed by PCR, sequencing and flow cytometry. The protective potential of
rMVA-DENV1 was tested in C57 / BL6 mice on a homologous dose-boosting
immunization schedule, followed by intracranial challenge with the corresponding
DENV. Animals were immunized with 107 pfu or 108 pfu of rVA-DENV1 and
challenged with DENV1 Mochizuki. During the challenge, they were monitored
evaluated through a SHIRPA protocol. Based on the results we can conclude that
the construction of the different recombinant viruses was effective, especially
rMVA-DENV1, the only one tested for protective capacity. The data generated in
this research can be added to those previously obtained for DENV3 in order to
obtain a tetravalent vaccine against DENV.